The Company is voluntarily discontinuing development of PGN-EDO51 and intends to wind down all DMD-related research and development activities. In the 10 mg/kg cohort (n=4) of the CONNECT1 study ...

In the phase 2 Connect1-EDO51 study, PepGen’s exon 51-skipping oligonucleotide PGN-EDO51 only increased dystrophin levels to 0.59% of normal levels in four patients in the 10-mg/kg cohort ...

PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates PepGen, Inc Updated Mon, Nov 14, 2022, 8:00 AM 9 min read ...

The anti-inflammatory role of EH was also demonstrated in an experimental mouse model of peritonitis induced by intraperitoneal PGN injection. The phosphatidylinositol 3-kinase (PI3K)/Akt pathway ...

PepGen Inc, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort ...